Zealand Pharma enters USD 200m financing agreement

With a financing agreement entailing up to USD 200m with private investment firm Oberland Capital, biotech firm Zealand Pharma wants to invest in its clinical pipline.

Photo: Zealand Pharma / PR

On Tuesday, Zealand Pharma announces a seven-year financing agreement worth up to USD 200m with private investment firm Oberland Capital, as reported in a press release.

Pursuant of the agreement, Zealand Pharma receives USD 100m as an upfront payment and is granted the option to receive an additional USD 50m before Dec. 31, 2023, on the condition that the biotech firm's drug candidate, glepaglutide, which is a potential treatment of short bowel syndrome (SBS), is approved by the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs